About Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive ...
Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines ...
Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that ...
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and ...
你知道我们的免疫系统是如何在与癌症的战斗中发挥关键作用的吗？近年来，科学家们对T细胞的研究不断深入，发现它们在控制疾病进程和免疫治疗效果方面的关键性。然而，CD4 T细胞在这一过程中所扮演的角色，直到最近才逐渐浮出水面。
Running for House Representative Seat A are incumbent Republican James Petzke and Democrat Catherine “Casey” Hess.
The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.
London, UK and Bristol, UK, 24 September 2024 – Quell Therapeutics Ltd (“Quell” or “the Company”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious ...
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...
2024年10月19日，赛尔欣生物宣布成功完成数千万人民币的融资，这笔资金将用于加速其Treg（调节性T细胞）细胞疗法的研发。此举被视为生物医药领域重要的一步，尤其是在自身免疫疾病和肿瘤免疫治疗领域的应用潜力引发广泛关注。 Treg细胞疗法，作为一种具有重要临床应用前景的免疫疗法，旨在通过调节免疫系统来帮助缓解多种疾病，包括糖尿病、类风湿关节炎等慢性疾病以及肿瘤。近年来，伴随着医疗技术的不断进步和 ...
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate development New CAR-Treg cell therapy ...
PolTREG is the only company to hold up to 12 years' worth of proprietary safety and efficacy data in patients with early-onset T1D for PTG-007, a polyclonal autologous Treg cellular therapy. The data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback